{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:21:06Z","timestamp":1773249666297,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473409"],"award-info":[{"award-number":["81473409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Innovation Fund","award":["18140900900"],"award-info":[{"award-number":["18140900900"]}]},{"name":"MHHFDU-SPFDU Joint Research Fund","award":["RO-MY201710"],"award-info":[{"award-number":["RO-MY201710"]}]},{"name":"Minhang Natural Science Fund of China","award":["2018MHZ055"],"award-info":[{"award-number":["2018MHZ055"]}]},{"name":"Foundation of Shanghai Municipal Commission of Health and Family Planning","award":["201840057"],"award-info":[{"award-number":["201840057"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.biopha.2019.109416","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T16:29:07Z","timestamp":1568132947000},"page":"109416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling"],"prefix":"10.1016","volume":"119","author":[{"given":"Size","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haishu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.109416_bib0005","series-title":"Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5","author":"Smith","year":"2009"},{"key":"10.1016\/j.biopha.2019.109416_bib0010","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1345\/aph.1C396","article-title":"Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction","volume":"37","author":"Sipe","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2019.109416_bib0015","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2019.109416_bib0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"Antons","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2019.109416_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4274(02)00010-3","article-title":"Myopathy and rhabdomyolysis with lipid-lowering drugs","volume":"128","author":"Hodel","year":"2002","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2019.109416_bib0030","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0035","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2019.109416_bib0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennernas","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.109416_bib0045","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1018923325359","article-title":"The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981","volume":"10","author":"Kearney","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2019.109416_bib0050","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5\u2032-diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2019.109416_bib0055","first-page":"1315","article-title":"Chemicals DtBFo: atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil","volume":"35","author":"Goosen","year":"2007","journal-title":"Fenofibrate Fenofibric Acid"},{"key":"10.1016\/j.biopha.2019.109416_bib0060","first-page":"1369","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.109.030254","article-title":"Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans","volume":"38","author":"Watanabe","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0070","first-page":"916","article-title":"Metabolism and excretion of atorvastatin in rats and dogs","volume":"27","author":"Black","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0075","article-title":"Dm, disposition: hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions","volume":"113","author":"Vildhede","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","article-title":"Effect of itraconazole on the pharmacokinetics of atorvastatin","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"Therapeutics: effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2019.109416_bib0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration\u2019s office of clinical pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.109416_bib0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejps.2015.06.019","article-title":"Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites","volume":"77","author":"Zhang","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.109416_bib0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13318-016-0383-9","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict drug-drug interactions (DDIs)","volume":"42","author":"Duan","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.109416_bib0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1007525616017","article-title":"Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter","volume":"17","author":"Wu","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2019.109416_bib0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/bdd.1784","article-title":"Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions","volume":"33","author":"Camenisch","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0115","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1007\/s11095-012-0792-7","article-title":"Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions","volume":"29","author":"Varma","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2019.109416_bib0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.31.10.942","article-title":"Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin","volume":"31","author":"Shin","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2019.109416_bib0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0091270010366446","article-title":"Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin","volume":"51","author":"Whitfield","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.109416_bib0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2004.07.008","article-title":"Therapeutics: substantially elevated levels of atorvastatin and metabolites in cyclosporine\u2010treated renal transplant recipients","volume":"76","author":"Hermann","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0140","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0150","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.4.7.909","article-title":"Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions","volume":"4","author":"Galetin","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2019.109416_bib0155","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00003088-200645100-00006","article-title":"Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4","volume":"45","author":"Brown","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.109416_bib0160","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2019.109416_bib0165","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9149(97)00907-7","article-title":"Rhabdomyolysis after taking atorvastatin with gemfibrozil","volume":"81","author":"Duell","year":"1998","journal-title":"Am. J. Cardiol."},{"issue":"100","key":"10.1016\/j.biopha.2019.109416_bib0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1024\/1661-8157\/a000491","article-title":"Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole","author":"Franz","year":"2011","journal-title":"Praxis (Bern 1994)"},{"key":"10.1016\/j.biopha.2019.109416_bib0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fonc.2017.00150","article-title":"Fatal statin-induced rhabdomyolysis by possible interaction with palbociclib","volume":"7","author":"Nelson","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2019.109416_bib0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40800-016-0036-6","article-title":"Rhabdomyolysis after coadministration of atorvastatin and sacubitril\/valsartan (Entresto) in a 63-year-old woman","volume":"3","author":"Faber","year":"2016","journal-title":"Drug Saf. Case Rep."},{"key":"10.1016\/j.biopha.2019.109416_bib0190","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1345\/aph.1A481","article-title":"Rhabdomyolysis with concurrent atorvastatin and diltiazem","volume":"36","author":"Lewin","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2019.109416_bib0195","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1345\/aph.19039","article-title":"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine","volume":"33","author":"Maltz","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2019.109416_bib0200","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.xphs.2017.01.007","article-title":"Evaluation of drug-drug interaction potential between Sacubitril\/Valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model","volume":"106","author":"Lin","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.109416_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jcph.792","article-title":"Physiologically based pharmacokinetic modeling of palbociclib","volume":"57","author":"Yu","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2019.109416_bib0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","article-title":"Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro","volume":"33","author":"Skottheima","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.109416_bib0215","first-page":"1","article-title":"Assessment of drug-drug interaction potential between atorvastatin and LCZ696, a novel angiotensin receptor neprilysin inhibitor, in healthy Chinese male subjects","volume":"42","author":"Ayalasomayajula","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.109416_bib0220","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.12447","article-title":"Physiologically-based pharmacokinetic modeling of atorvastatin incorporating delayed gastric emptying and acid-to-lactone conversion","author":"Morse","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.biopha.2019.109416_bib0225","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.110.032268","article-title":"Chemicals DtBFo: cyclosporine a, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin","volume":"38","author":"Amundsen","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.109416_bib0230","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s005350070044","article-title":"Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance","volume":"35","author":"Kamisako","year":"2000","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2019.109416_bib0235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","article-title":"Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2\/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction","volume":"311","author":"Yoshihisa","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0240","first-page":"F326","article-title":"Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter","volume":"270","author":"Kanai","year":"1996","journal-title":"J. Am. J. Physiol."},{"key":"10.1016\/j.biopha.2019.109416_bib0245","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13318-016-0328-3","article-title":"Pharmacokinetics, safety and tolerability of Sacubitril\/Valsartan (LCZ696) after single-dose administration in healthy Chinese subjects","volume":"42","author":"Han","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.109416_bib0250","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2019.109416_bib0255","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0260","first-page":"1281","article-title":"Drug interactions and the statins","volume":"161","author":"Herman","year":"1999","journal-title":"CMAJ"},{"key":"10.1016\/j.biopha.2019.109416_bib0265","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2019.109416_bib0270","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab. Dispos."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219323583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219323583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:06:19Z","timestamp":1731427579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219323583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":54,"alternative-id":["S0753332219323583"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109416","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109416"}}